A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA)
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
NGM Biopharmaceuticals, Inc.
Start Date
March 19, 2021
End Date
March 14, 2026
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
NGM Biopharmaceuticals, Inc.
Start Date
March 19, 2021
End Date
March 14, 2026